Evidence map›Paper›PMID 41080970›Full record

Trial reportGates open research2025

Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria Chemoprevention in Sierra Leone.

Haily Chen, Kwabena Owusu-Kyei, Augustin E Fombah, Julian Williams, Carla García-Fernández, Eduard Rovira-Vallbona, Andreu Bofill, Llorenç Quintó, Antía Figueroa-Romero, Falama Mac-Abdul and 3 more

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gates open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04235816 (Evaluation of the Impact on Childhood Mortality of Azithromycin Plus Intermittent Preventive Treatment Administered Through the Expanded Program on Immunization in Sierra Leone), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04235816 phase3active not recruitingnot on this map

Evaluation of the Impact on Childhood Mortality of Azithromycin Plus Intermittent Preventive Treatment Administered Through the Expanded Program on Immunization in Sierra Leone

TypeinterventionalSponsorBarcelona Institute for Global HealthRan2021 to 2026Enrolled20,560ConditionsChild MortalityArmsAzithromycin, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Haily Chen *ISGlobal, Barcelona, Spain.
Kwabena Owusu-Kyei *ISGlobal, Barcelona, Spain.ORCID https://orcid.org/0009-0006-3733-7936
Augustin E FombahISGlobal, Barcelona, Spain.
Julian WilliamsUniversity of Sierra Leone College of Medicine and Allied Health Sciences, Freetown, Western Area, Sierra Leone.
Carla García-FernándezISGlobal, Barcelona, Spain.
Eduard Rovira-VallbonaISGlobal, Barcelona, Spain.
Andreu BofillISGlobal, Barcelona, Spain.
Llorenç QuintóISGlobal, Barcelona, Spain.ORCID https://orcid.org/0000-0001-9992-6951
Antía Figueroa-RomeroISGlobal, Barcelona, Spain.ORCID https://orcid.org/0000-0003-4682-1421
Falama Mac-AbdulMinistry of Health, Freetown, Sierra Leone.
Mohamed SamaiUniversity of Sierra Leone College of Medicine and Allied Health Sciences, Freetown, Western Area, Sierra Leone.
Alfredo MayorISGlobal, Barcelona, Spain.
Clara MenéndezISGlobal, Barcelona, Spain.ORCID https://orcid.org/0000-0002-2641-6907

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Monitoring parasite resistance to antimalarial drugs is essential for detecting potential changes in drug efficacy. This study assessed the prevalence of molecular markers of resistance to sulfadoxine-pyrimethamine (SP), chloroquine, and artemisinin in Sierra Leone, where SP is used for intermittent preventive treatment in pregnancy (IPTp) and perennial malaria chemoprevention (PMC) in young children, while artemisinin is used to treat malaria episodes. Methods: A cross-sectional survey was conducted between June and August 2021 in three districts of Sierra Leone. A total of 440 febrile children aged 2-5 years attending the health facilities were screened for Results: Of 298 blood samples, 237 (79.5%) were qPCR-positive and 230 samples were successfully genotyped. The Conclusion: In this study, the sustained low prevalence of Trial registration: Clinicaltrials.gov NCT04235816. Registered on January 17, 2020.

Indexed as

AntimalarialsDrug ResistanceMalaria, FalciparumPlasmodium falciparumArtemisininsChemopreventionChild, PreschoolChloroquineCross-Sectional StudiesDrug CombinationsFemaleHumansMalePrevalenceProtozoan ProteinsPyrimethamineAntimalarialsartemisininArtemisininsChloroquineDrug Combinationsfanasil, pyrimethamine drug combinationProtozoan ProteinsPyrimethamineSulfadoxinechemopreventionIPTimalariaPMCresistanceSierra Leonesulfadoxine-pyrimethamineU5

Identifiers

PMID41080970
PMCPMC12508423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.